Sage Group PLC SGE shares advanced 1.20% to £13.11 Tuesday, on what proved to be an all-around rough trading session for ...
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...
Sage Group Plc jumped to a record high after the UK software company announced a share buyback plan of as much as £400 ...
RBC Capital Markets has upgraded Sage Therapeutics (NASDAQ:SAGE) to sector perform from underperform, stating it expects the ...
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as ...
Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...
Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington's disease after it failed a mid-stage study, the drug developer said on ...
Sage reports a 23% surge in cloud revenue to £732m, fuelled by AI innovation, new customer growth and global cloud adoption ...
A group of University of Wyoming researchers has been recognized by The Wildlife Society for a multifaceted study on the ...
A major set of Valorant patch notes have just dropped, with big nerfs coming to the likes of Cypher and Omen and a brand new ...
A super creamy sage and butternut squash mac n cheese. This post was originally published on Nov. 16 2020 and was updated ...